RXST

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.e618d017.1786388560.cf8effdc

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

EX-99.1

2 rxst-ex99_1.htm

EX-99.1

EX-99.1

Exhibit 99.1

RXSIGHT, INC. ANNOUNCES PRELIMINARY SECOND QUARTER FINANCIAL RESULTS AND PRODUCT PIPELINE UPDATES FOLLOWING STRATEGIC COLLABORATION AGREEMENT

Aliso Viejo, Calif. – July 6, 2026 – RxSight, Inc. (NASDAQ: RXST) today announced select preliminary financial results for the second quarter of 2026 and updates to its standalone product pipeline, following the announcement of the company’s strategic collaboration with Alcon to develop and commercialize light-adjustable Presbyopia-Correcting Intraocular Lenses.

Preliminary Second Quarter 2026 Results

• Total company revenue is expected to be approximately $32 to $34 million, which includes,

o $5 to $7 million in revenue recognized from the RxSight Alcon Strategic Collaboration, with the specific amount expected to be reported with the Company’s financial results for the second quarter of 2026 in August 2026.

• Sales of approximately $27 million, which includes,

o the sale of 24,917 Light Adjustable Lens (LAL®) units; and

o 11 Light Delivery Devices (LDD™) units; 1 rental unit placed.

• Cash, cash equivalents and short-term investments of approximately $209 million as of June 30, 2026.

Pipeline Highlights

• Next-generation RxSight Light Adjustable Technology™ platform, with intermediate-term launches of new LAL®, LAL +®, and LAL Toric lenses with improved workflow and fewer required post-operative treatments.

• Collaboration with Alcon to innovate our respective platforms to develop and commercialize light-adjustable Presbyopia-Correcting Intraocular Lenses (Simultaneous Vision Intraocular Lenses).

“While we faced meaningful commercial headwinds in Q2, including from more widespread competitive trialing, the unique ability of RxSight’s Light Adjustable Technology to customize visual outcomes continued to deliver significant clinical benefits to thousands of patients around the world,” said Dr. Ron Kurtz, Chief Executive Officer and President of RxSight. “To position the company for deeper penetration of current, next-generation, and collaboration products, we are accelerating investments in our LAL sales force and commercial capabilities, while maintaining a disciplined approach to overall spending. By leveraging our differentiated technology, large customer base, strong balance sheet and exciting pipeline, we believe RxSight is well positioned to drive both high-margin implant sales and future royalty income, thereby empowering doctors to deliver the industry’s premier outcomes for even more of their patients.”

Updated Product Pipeline

RxSight is developing the first and only suite of adjustable IOLs built on its next-generation Light Adjustable Lens technology platform with improved workflow and enhanced performance. Highlights include:

• Next-generation LAL, designed to deliver best-in-class visual quality and optical clarity, with post-operative refractive optimization to consistently achieve targeted visual outcomes;

• Next-generation LAL+, designed to improve intermediate vision for everyday activities while preserving high-quality optical performance, with adjustability enabling precise refractive targeting;

• LAL Toric, designed with built-in astigmatism correction, while still enabling post-operative refinement of residual sphere and cylinder to maximize uncorrected visual acuity.

Updated 2026 Guidance

• 2026 full-year revenue of $140 to $160 million, inclusive of RxSight sales and revenue recognized from the RxSight Alcon Strategic Collaboration, comprised of:

o Sales of $110 to $120 million, below previous guidance of $120 to $135 million

o Collaboration Agreement revenue of $30 to $40 million, subject to the terms and conditions described in the Current Report on Form 8-K filed with the Securities and Exchange Commission (SEC) on or about the date hereof;

• Gross margin of 73% to 75%, above previous guidance of 70% to 72%; and

• Operating expense at the high-end of $150 to $160 million, in line with previous guidance

The foregoing financial and operational results are preliminary estimates. RxSight is in the process of finalizing its financial statements for the second quarter of 2026, and its actual results remain subject to completion of those financial statements and their review by its independent registered public accounting firm. These preliminary estimates are based on information available to management as of the date of this press release and certain related assumptions, which could prove incorrect. RxSight’s actual, reported results of operations could differ based on completion of our quarter end closing procedures, final adjustments and developments that may arise prior to completion of its quarterly financial statements, and adjustments arising from the review by its independent registered public accounting firm. You should carefully review RxSight’s unaudited, consolidated financial statements for the second quarter of 2026 when they become available.

Conferenc

EX-99.1

2 rxst-ex99_1.htm

EX-99.1

EX-99.1

Exhibit 99.1

RXSIGHT, INC. REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES FULL-YEAR SALES OUTLOOK

Aliso Viejo, Calif. – May 6, 2026 – RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended March 31, 2026.

Strategic Highlights and Recent Developments

• Q1 sales of $30.9 million driven by 27,472 Light Adjustable Lens (LAL) units

• 20 Light Delivery Devices (LDDs) sold in Q1, expanding the installed base to 1,154 units

• Robust clinical data presented at the recent American Society of Cataract and Refractive Surgery (ASCRS) annual meeting highlighting the versatility and impact of adjustability

• Recent regulatory approval in New Zealand furthering the company’s international footprint and global market opportunity

• 2026 sales and gross margin guidance unchanged; operating expense expected to be at high end of previous range reflecting targeted investments in strategic growth initiatives

“We are encouraged by the stabilizing business trends and the initial progress from our ongoing commercial initiatives,” said Ron Kurtz, President and Chief Executive Officer of RxSight. “As we continue to refine these efforts, investing in both our team and our pipeline, we are confident that we can continue to build momentum across the company and reach the full potential of our technology for patients and practices.”

First Quarter Financial Results

In the first quarter of 2026, the company reported sales of $30.9 million, down 18.5% compared to the prior year, largely reflecting lower LDD unit volumes, consistent with expectations. LAL procedures decreased 0.4% year over year.

First quarter gross profit margin of 76.1% increased from 74.8% in the prior‑year period, primarily driven by a favorable shift in product mix toward LAL sales.

Total operating expenses were $41.3 million versus $39.0 million in the year-ago period. The increase was primarily driven by the continued expansion of our global commercial and support teams.

In the first quarter of 2026, the company reported a net loss of $(15.9) million, or $(0.38) per basic and diluted share, compared to a net loss of $(8.2) million, or $(0.20) per basic and diluted share in the first quarter of 2025. Adjusted net loss in the first quarter of 2026 was $(7.9) million, or $(0.19) per basic and diluted share, compared to an adjusted net loss of $(1.1) million, or $(0.03) per basic and diluted share in the first quarter of 2025.

As of March 31, 2026, cash, cash equivalents and short-term investments totaled $217.9 million.

2026 ASCRS Highlights

At the recent ASCRS annual meeting, RxSight technology was featured across multiple scientific presentations addressing refractive accuracy, complex cases and evolving treatment strategies. This rapidly expanding body of clinical evidence highlighted both the versatility and impact of adjustability. In addition, the conference included presentations by Dr. Szabo, who reported binocular LAL outcomes in which 93.1% of patients achieved simultaneous 20/20 or better distance and J1 or better near, as well as a meta-analysis by Dr. Rabinovitch, demonstrating pooled accuracy with the LAL was 91.2% within 0.50 diopters of target refraction.

2026 Guidance

The company’s 2026 financial guidance is as follows:

• Revenue of $120 to $135 million, in-line with previous guidance

• Gross margin of 70% to 72%, in-line with previous guidance

• Operating expenses expected to be at the high-end of previous $150 to $160 million range

• Non-cash stock-based compensation expense of $30 to $32 million, in-line with previous guidance

Conference Call

On Wednesday, May 6, 2026, at 1:30 p.m. Pacific Time, the company will host a conference call to discuss its first quarter 2026 financial results. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963 and enter the conference code: 2630350. The call will also be broadcast live in listen-only mode via a link on the company’s investor relations website at https://investors.rxsight.com/. An archived recording of the call will be available through the same link shortly after its completion.

About RxSight, Inc.

RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens (LAL/LAL+, collectively the “LAL”), RxSight Light Delivery Device (LDD) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.

Forward-Looking Statements

This press release contains forward-looking statements, including: including statements regarding the company’s expectations related to stabilizing busin